* Ardelyx Inc reported quarterly breakeven results per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of ten analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -8 cents to -1 cents per share.
* Revenue rose 74.2% to $98.24 million from a year ago; analysts expected $86.64 million.
* Ardelyx Inc's reported EPS for the quarter was breakeven results.
* The company reported a quarterly loss of $809 thousand.
* Ardelyx Inc shares had fallen by 14.5% this quarter and lost 5.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 5.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Ardelyx Inc is $11.00 This summary was machine generated from LSEG data November 1 at 03:33 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.05 0.00 Beat
Jun. 30 2024 -0.11 -0.07 Beat
Mar. 31 2024 -0.15 -0.11 Beat
Dec. 31 2023 -0.09 -0.12 Missed
Comments